New hope for kidney transplant patients: safer CMV prevention on the horizon?
NCT ID NCT06001320
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a newer drug, letermovir, works better and causes fewer side effects than the standard drug valganciclovir for preventing CMV infection in African American kidney transplant recipients. About 30 high-risk patients will take letermovir for 6 months after transplant, and their results will be compared to a similar group from the past who took valganciclovir. The goal is to reduce the risk of CMV-related illness and side effects like low white blood cell counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
VCU Medical Center
Richmond, Virginia, 23219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test could tailor CMV prevention after stem cell transplants
- Pre-Surgery bootcamp may boost kidney transplant recovery
- Simple bathroom habit may cut infection risk after kidney transplant
- New drug may offer safer CMV prevention for kidney transplant patients
- Urine test may catch kidney rejection before it's too late
- Baking soda study for kidney patients pulled before it started